Stephen L. Hoffman, M.D., Joins Celera Genomics as Senior Vice President, Immunotherapeutics
Rockville, MD - January 10, 2001
Celera Genomics (NYSE: CRA), an Applera Corporation business, announced today that Stephen L. Hoffman, M.D., has joined Celera as senior vice president, immunotherapeutics.
In this new position, Dr. Hoffman will establish and lead a team to create and implement scientific and technical programs designed to develop Celera's potential new discoveries in its proteomics and functional genomics initiatives. Celera intends to uncover important disease targets from its genomics and proteomics data, and to develop vaccines, therapeutic antibodies, and other biologically active molecules for treating and preventing these diseases. Dr. Hoffman and his team will initially focus on specific cancers.
Dr. Hoffman has been a pioneer in translating genomic information into DNA vaccines and moving often-complex genetic vaccines from the laboratory to the clinic, thereby creating an entirely new approach to disease vaccine development. He is a world-renowned expert in tropical medicine, especially malaria and malaria vaccine development, and is currently president of the American Society of Tropical Medicine and Hygiene. He was instrumental in sequencing the genome of the microbe responsible for malaria, Plasmodium falciparum, and bringing the technologies of functional genomics and proteomics to malaria research. Dr. Hoffman comes to Celera from the United States Navy, where he directed malaria research efforts since 1987. He was also an attending physician in infectious diseases.
“We are pleased to have Steve join us as he brings substantial expertise in the development of genomic-based vaccines,” said J. Craig Venter, Ph.D., Celera’s president and chief scientific officer. “We believe his broad scientific, regulatory, clinical, and management experience should integrate well with the management strengths that Celera has in place in oncology and proteomics, which should allow us to develop the drug discovery potential that lies within Celera’s genomic and proteomic information.”
Applera Corporation, formerly PE Corporation, comprises two operating groups. The Celera Genomics Group, headquartered in Rockville, MD, intends to be the definitive source of genomic and related medical information. Celera has developed three business units: the On-line Information Business, Discovery Sciences, and Discovery Services, all of which build upon Celera’s generation, integration, and analysis of biological information. Celera intends to enable therapeutic discoveries both through its own application of its scientific capabilities and in partnership with pharmaceutical and biotechnology companies. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Customers use these tools to analyze nucleic acids (DNA and RNA) and proteins in order to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.4 billion during fiscal 2000. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com, or by telephoning 800.762.6923.
Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.